References
- Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev 2015;25:1-12
- GLOBOCAN2012 Estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Lyon (France): International Agency for Research on Cancer; [cited 2017 Feb 24]. Available from: http://globocan.iarc.fr/Pages/fact_sheets.cancer.aspx
- The surveillance, epidemiology, and end results (SEER) program of the National Cancer Institute [Internet]. Rockville (MD): National Cancer Institute; [cited 2017 Feb 24]. Available from: https://seer.cancer.gov/statfacts/html/prost.html
- Ukawa S, Nakamura K, Okada E, et al. Clinical and histopathological characteristics of patients with prostate cancer in the BioBank Japan project. J Epidemiol 2017;27(3S):65-70
- Mariotto AB, Robin Yabroff K, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011;103:117-28
- Kitazawa T, Matsumoto K, Fujita S, et al. Cost of illness of the prostate cancer in Japan—a time-trend analysis and future projections. BMC Health Serv Res 2015;15:453
- Akaza H. Advanced prostate cancer treatment guidelines: a global perspective; trends of hormone therapy in Japan. BJU Int 2004;94(Suppl3):5
- The Japanese Urological Association. Practice guideline for prostate cancer in 2016. Tokyo (Japan): Kanehara & Co., Ltd; 2016 (Japanese)
- Sethi R, Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging 2009;4:259-67
- Suzuki K, Namiki M, Fujimoto T, et al. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: A Phase III, randomized, open-label, parallel-group, comparative study in Japan. Jpn J Clin Oncol 2015;45:1168-74
- Morris S, Devlin N, Parkin D, et al. Economic analysis in healthcare, 2nd Edition. Hoboken (NJ): Wiley;2012
- Robinson R. Cost-benefit analysis. Brit Med J 1993;307:924-6
- Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA 1989;262:2879-86
- Shanahan M, Ritter A. Cost benefit analysis of two policy options for cannabis: Status quo and legalisation. PLoS One 2014;9:e95569
- Anders B, Ommen O, Pfaff H, et al. Direct, indirect, and intangible costs after severe trauma up to occupational reintegration – an empirical analysis of 113 seriously injured patients [Direkte, indirekte und intangible kosten nach einem schweren trauma]. GMS Psychosoc Med 2013;10:1-15
- Social Insurance Laboratory. Interpretation of Medical Fee Schedule Table. Tokyo (Japan): Social Insurance Laboratory Co. Ltd; 2016 (Japanese)
- Guideline for preparing cost-effectiveness evaluation to the central social insurance medical council [Internet]. Tokyo (Japan): Central Social Insurance Medical Council; [cited 2017 Feb 24]. Available from: http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000109789.pdf
- Statistical classification of diseases and cause of death (In Japanese) [Internet]. Tokyo (Japan): Ministry of Health, Labour and Welfare; [cited 2017 Feb 24]. Available from: http://www.mhlw.go.jp/toukei/sippei/
- Japanese Basic Survey on Wage Structure on 2016 (In Japanese) [Internet]. Tokyo (Japan): Ministry of Health, Labour and Welfare; [cited 2017 Feb 24]. Available from: http://www.mhlw.go.jp/toukei/itiran/roudou/chingin/kouzou/z2015/dl/13.pdf/
- Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Berlin (Germany): Springer Science & Business Media; 2007
- Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 2016;34:2925-33
- National Health Insurance drug price list on 2017 Feb 15 [Internet]. Tokyo (Japan): Ministry of Health, Labour and Welfare; [cited 2017 Feb 24]. Available from: http://www.mhlw.go.jp/topics/2016/04/tp20160401-01.html
- Hauber AB, González JM, Groothuis-Oudshoorn CGM, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health 2016;19:300-15
- Brett Hauber A, Nguyen H, Posner J, et al. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin 2016;32:251-62
- Qin L, Chen S, Flood E, et al. Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-naïve patients with type 2 diabetes mellitus: a multinational preference study. Diabetes Ther 2017;8:321-334